Cargando…

Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability

Development of next-generation oncolytic viruses requires the design of vectors that are potently oncolytic, immunogenic in human tumors, and well tolerated in patients. Starting with a joint-region deleted herpes simplex virus 1 (HSV-1) to create large transgene capability, we retained a single cop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kennedy, Edward M., Farkaly, Terry, Grzesik, Peter, Lee, Jennifer, Denslow, Agnieszka, Hewett, Jacqueline, Bryant, Jeffrey, Behara, Prajna, Goshert, Caitlin, Wambua, Daniel, De Almeida, Ana, Jacques, Judith, Deavall, Damian, Rottman, James B., Glorioso, Joseph C., Finer, Mitchell H., Haines, Brian B., Quéva, Christophe, Lerner, Lorena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479328/ https://www.ncbi.nlm.nih.gov/pubmed/32953982 http://dx.doi.org/10.1016/j.omto.2020.08.004

Ejemplares similares

Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer
por: Kennedy, Edward M., et al.
Publicado: (2022)

Expression of HSV-1 Receptors in EBV-Associated Lymphoproliferative Disease Determines Susceptibility to Oncolytic HSV
por: Wang, Pin-Yi, et al.
Publicado: (2012)

Oncolytic HSV: Underpinnings of Tumor Susceptibility
por: Kangas, Chase, et al.
Publicado: (2021)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
por: Migliarese, Christian, et al.
Publicado: (2023)

Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity
por: Leddon, Jennifer L, et al.
Publicado: (2015)

In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
por: Jahan, Nusrat, et al.
Publicado: (2021)

oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy
por: Sahu, Upasana, et al.
Publicado: (2023)

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017)

Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy
por: Friedman, Gregory K., et al.
Publicado: (2013)

The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles
por: Tang, Guijin, et al.
Publicado: (2023)

Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy
por: Robilotti, Elizabeth, et al.
Publicado: (2023)

STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells
por: Okemoto, Kazuo, et al.
Publicado: (2013)

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
por: Menotti, Laura, et al.
Publicado: (2018)

Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles
por: Fu, Xinping, et al.
Publicado: (2018)

The modality and redundancy effects in multimedia learning in children with dyslexia
por: Knoop‐van Campen, Carolien A. N., et al.
Publicado: (2018)

Enhancing The Bystander Killing Effect Of An Oncolytic HSV By Arming It With A Secretable Apoptosis Activator
por: Loya, Shana Marie Williamson, et al.
Publicado: (2015)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
por: Koch, Marilin S., et al.
Publicado: (2020)

Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1
por: Hoang, Huy-Dung, et al.
Publicado: (2023)

Engineered HSV vector achieves safe long-term transgene expression in the central nervous system
por: Verlengia, Gianluca, et al.
Publicado: (2017)

The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment
por: Uche, Ifeanyi Kingsley, et al.
Publicado: (2021)

Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability
por: Howard, Faith, et al.
Publicado: (2022)

Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors
por: Abdoli, Shahriyar, et al.
Publicado: (2017)

HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain
por: Hao, Shuanglin, et al.
Publicado: (2006)

Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002
por: Ring, Eric K., et al.
Publicado: (2017)

Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas
por: Monie, Dileep D., et al.
Publicado: (2021)

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
por: Simpson, G R, et al.
Publicado: (2012)

Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host’s Innate Antiviral Immunity to Attack Tumor Cells
por: Fu, Xinping, et al.
Publicado: (2020)

Cell type-specific response of colon cancer tumor cell lines to oncolytic HSV-1 virotherapy in hypoxia
por: Shayan, Sara, et al.
Publicado: (2022)

EPCT-22 SAFETY AND EFFICACY OF INTRAVENTRICULAR IMMUNOVIROTHERAPY WITH ONCOLYTIC HSV-1 G207 FOR TREATMENT OF LEPTOMENINGEAL DISEASE
por: Kang, Kyung-Don, et al.
Publicado: (2021)

Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus
por: Ding, Jun, et al.
Publicado: (2022)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

Novel mutations in U(L)24 and gH rescue efficient infection of an HSV vector retargeted to TrkA
por: Marzulli, Marco, et al.
Publicado: (2023)

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2014)

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
por: Leoni, Valerio, et al.
Publicado: (2015)

An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites
por: Fu, Xinping, et al.
Publicado: (2014)

Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy
por: Ravirala, Divya, et al.
Publicado: (2021)

Stonewall and Brickwall: Two Partially Redundant Determinants Required for the Maintenance of Female Germline in Drosophila
por: Shukla, Vallari, et al.
Publicado: (2018)

Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment
por: Jackson, Joseph W., et al.
Publicado: (2021)

Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models
por: Braidwood, Lynne, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_uklbos4gho56piso3f10k4pv64